Pharmexa obtains global license to Provax® from Biogen Idec
Jakob Schmidt, CEO in Pharmexa says: "In-licensing is an important part of Pharmexa's strategy, and we are very pleased that we now have broad access to Provax®. We recently expanded our license to the PADRE® epitope from Epimmune and signed an agreement with Antigenics concerning the adjuvant QS-21 for use in our HER-2 AutoVac(TM) Protein breast cancer program. Each of these agreements secures us access to technologies that complement and strengthen our proprietary technology platform within immunotherapy."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.